1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030

Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030

  • June 2021
  • 175 pages
  • ID: 6097026
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the colorectal cancer drugs market are Merck & Co. Inc., Roche, Sanofi, Amgen, and Pfizer, Inc.

The global colorectal cancer drugs market is expected to decline from $6.23 billion in 2020 to $6.09 billion in 2021 at a compound annual growth rate (CAGR) of -2.2%. The slow decline is mainly due to the outbreak of COVID-19 that has led to decrease in demand for immunocompromised treatments. The market is expected to reach $6.85 billion in 2025 at a CAGR of 3%.

The colorectal cancer drugs market consists of sale of colorectal cancer drugs.Colorectal cancer (CRC) or bowel cancer, is the cancer affecting large intestine and the rectum.

They are also named, colon tumor or rectal cancer depending upon where they begin.

The market covered in this report is segmented by type into vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/pd1 ligand 1 (pd1/pdl1) inhibitors, braf or mek inhibitors, tyrosine kinase (tki) inhibitors, immunomodulators; by distribution channels into hospitals pharmacies, retail pharmacies, others; by class into immunotherapy, chemotherapy, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market.Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power.

Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective.For example, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab and panitumumab.

The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy.Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules.

Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion.The transaction is expected to create a leading specialty company which would address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities.

Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

The number of colorectal cancer worldwide has been increasing.According to the American Cancer Society (ACS) estimates, there will be around 101,420 new cases of colon cancer and around 44,180 new cases of rectal cancer that would be registered in the USA in 2019.

The diagnosed incident cases of colorectal cancer are expected to increase by 27.3% to 672,400 cases by 2037. The reason for this increase can be attributed to factors such as low-fiber diet, obesity, consumption of alcohol and tobacco amongst others. The increase in number of colorectal cases will add to the overall size of the global colorectal cancer drugs market.

The colorectal cancer industry is governed by regulatory framework laid down by agencies such as US Food and Administration Agency (FDA), European Medicines Agency (EMA), American Society of Clinical Oncology (ASCO), and others.For instance, FDA’s recommendation for colorectal cancer drugs industry in the form of guidelines are mentioned within the CFR ’s (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from A to I.

The sub-part E deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as colorectal cancer. It also includes guidelines for the monitoring and evaluation of clinical trials of colorectal cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on